Baidu
map

胸心外科

订阅

MedSci主页 / 所有栏目 / 胸心外科

不同DES在CTO病变中的复合应用

2015-12-02 网络 MedSci原创

CTO病变医学图片
关注

不同DES在CTO病变中的复合应用

不同DES在CTO病变中的复合应用

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1993675, encodeId=4c3b19936e539, content=<a href='/topic/show?id=675254302e' target=_blank style='color:#2F92EE;'>#CTO病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5430, encryptionId=675254302e, topicName=CTO病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Wed Jun 01 11:11:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862752, encodeId=b4831862e52c8, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Wed Apr 06 06:11:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558497, encodeId=d187155849e54, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564506, encodeId=968915645060e, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=)]
    2016-06-01 12498f17m66暂无昵称

    #CTO病变#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1993675, encodeId=4c3b19936e539, content=<a href='/topic/show?id=675254302e' target=_blank style='color:#2F92EE;'>#CTO病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5430, encryptionId=675254302e, topicName=CTO病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Wed Jun 01 11:11:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862752, encodeId=b4831862e52c8, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Wed Apr 06 06:11:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558497, encodeId=d187155849e54, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564506, encodeId=968915645060e, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=)]
    2016-04-06 gao_jian4217

    #CTO#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1993675, encodeId=4c3b19936e539, content=<a href='/topic/show?id=675254302e' target=_blank style='color:#2F92EE;'>#CTO病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5430, encryptionId=675254302e, topicName=CTO病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Wed Jun 01 11:11:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862752, encodeId=b4831862e52c8, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Wed Apr 06 06:11:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558497, encodeId=d187155849e54, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564506, encodeId=968915645060e, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=)]
    2015-12-04 fusion

    #DES#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1993675, encodeId=4c3b19936e539, content=<a href='/topic/show?id=675254302e' target=_blank style='color:#2F92EE;'>#CTO病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5430, encryptionId=675254302e, topicName=CTO病变)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5742500212, createdName=12498f17m66暂无昵称, createdTime=Wed Jun 01 11:11:00 CST 2016, time=2016-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1862752, encodeId=b4831862e52c8, content=<a href='/topic/show?id=0b69542242' target=_blank style='color:#2F92EE;'>#CTO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5422, encryptionId=0b69542242, topicName=CTO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c66088, createdName=gao_jian4217, createdTime=Wed Apr 06 06:11:00 CST 2016, time=2016-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558497, encodeId=d187155849e54, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1564506, encodeId=968915645060e, content=<a href='/topic/show?id=b68a586365' target=_blank style='color:#2F92EE;'>#DES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5863, encryptionId=b68a586365, topicName=DES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=432c14994935, createdName=fusion, createdTime=Fri Dec 04 00:11:00 CST 2015, time=2015-12-04, status=1, ipAttribution=)]
    2015-12-04 fusion

    #DES#

    0

相关资讯

Am J Cardiol：伴CABG病史患者的CTO病变 PCI复合方法可行

美国一项研究表明，与不伴冠脉旁路移植术(CABG)病史的患者相比，通过复合方法(“hybrid” crossing algorithm)对伴CABG病史患者的慢性完全闭塞病变实施经皮冠脉介入(CTO PCI)的成功率稍低，但并发症发生率相似。论文于4月2日在线发表于《美国心脏病学杂志》(Am J Cardiol)。 此项研究共纳入496例接受CTO PCI治疗的序贯性患者，并对伴和不伴CABG病

Baidu
map
Baidu
map
Baidu
map